Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients
NCT ID: NCT00622934
Last Updated: 2010-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2007-07-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One of the most problems in the intensive care unit is stress response. we are going to evaluate effects of erythropoietin on oxidative stress and inflammation in trauma patient in intensive care unit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
erythropoietin
300mg/kg erythropoietin 3 times on the first week of admission
2
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
erythropoietin
300mg/kg erythropoietin 3 times on the first week of admission
placebo
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Allergy
* Erythroid leukemia
* Pregnancy and breast feeding
* Pre operative patient
* Severe cardiovascular and cerebrovascular diseases
* Thromboembolic disorders
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pharmaceutical Sciences Research Center Tehran University of Medical SCIENCES
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MOJTABA MOJTAHEDZADE
Role: STUDY_CHAIR
TUMS
MOSTAFA MOHAMMADY
Role: PRINCIPAL_INVESTIGATOR
TUMS
MOJTABA MOJTAHED
Role: STUDY_DIRECTOR
TUMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sina Hospital
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
MOJTAHEDZADE
Role: primary
MOHAMMADY
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
425/195 13/4/86
Identifier Type: -
Identifier Source: org_study_id